Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test could personalize lung cancer care, avoid unnecessary chemo

NCT ID NCT04166487

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 21 times

Summary

This study tests whether a blood test taken during treatment can show if immunotherapy (pembrolizumab) is working well enough alone, or if adding chemotherapy is needed. About 40 people with stage IV non-small cell lung cancer will give blood samples at different times. The goal is to use this information to tailor treatment and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Boston Medical Center

    Boston, Massachusetts, 02118, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Dana-Farber at Steward St. Elizabeth's Medical Center

    Brighton, Massachusetts, 02135, United States

  • Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital

    South Weymouth, Massachusetts, 02190, United States

Conditions

Explore the condition pages connected to this study.